Jordan Graham
Internal Medicine · New Orleans, LANPI 1649768409
Payments from drug & device makers
What this record shows
This record is dominated by grants: $18,000 of the $24,883 with a category attached, or 72.3%. Abbott accounts for 74.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $19,718 and has fallen 92.2% since, to $1,544 in 2025. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $152.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Boston Scientific$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$698
- Medtronic$609
- Edwards Lifesciences$491
- Novo Nordisk$427
- plus $3K from 23 others
What the payments were for
- Grants$18,00072%
- Food & beverage$6,78827%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $18,498 |
| Boston Scientific | 15 | $1,085 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $698 |
| Medtronic | 7 | $609 |
| Edwards Lifesciences | 11 | $491 |
| Novo Nordisk | 6 | $427 |
| Abiomed | 13 | $424 |
| Shockwave Medical, Inc | 4 | $414 |
| Pfizer | 12 | $388 |
| Novartis | 13 | $333 |
| Amgen | 10 | $302 |
| Teleflex LLC | 2 | $288 |
| AstraZeneca | 12 | $247 |
| E.r. Squibb & Sons, L.L.C. | 8 | $174 |
| Kestra Medical Technology Services, Inc. | 4 | $86 |
| Boehringer Ingelheim | 3 | $67 |
| Johnson & Johnson | 4 | $66 |
| Biotronik Inc. | 3 | $58 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| BD | 1 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Livanova USA, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Inari Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$322
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$300
- COREVALVE EVOLUT R$247
- LifeVest$200
- GUIDELINER$180
- OPTICROSS$169
- AMPLATZER AMULET$146
- SAPIEN 3 Ultra RESILIA$141
- Repatha$121
- AVVIGO Guidance System$116
- Watchman$114
- SYMPLICITY G3$108
- TRAPLINER$108
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$103
- VYNDAQEL$100
How this compares
$24,883 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 30 | $40,378 |
| JardianceEmpagliflozin | 42 | $37,422 |
| EliquisApixaban | 32 | $28,692 |
| BrilintaTicagrelor | 17 | $11,769 |
| Repatha SureclickEvolocumab | 11 | $5,799 |
| Metoprolol Succinate | 23 | $499 |
| ClopidogrelClopidogrel Bisulfate | 34 | $470 |
| Ezetimibe | 18 | $412 |
| Atorvastatin Calcium | 35 | $371 |
| Rosuvastatin Calcium | 16 | $343 |
| Carvedilol | 27 | $192 |
| Amlodipine Besylate | 36 | $190 |
| Chlorthalidone | 12 | $147 |
| Hydrochlorothiazide | 26 | $129 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 19 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $333 | $40,37830 claims |
| Boehringer IngelheimJardiance | $67 | $37,42242 claims |
| PfizerEliquis | $388 | $28,69232 claims |
| AstraZenecaBrilinta | $247 | $11,76917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- Steven DeitelzweigNew Orleans$939K
- Daniel EnglertNew Orleans$74K
- Pavan ChavaNew Orleans$24K
- Susan KaramNew Orleans$22K
- Arti ThanguduNew Orleans$20K
- David BrownNew Orleans$17K
- Peter PantlinNew Orleans$13K
- Genevieve MarongeNew Orleans$12K
- Samiullah ArshadNew Orleans$12K
- John WiseNew Orleans$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.